Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a downturn in stock indices, yet there is significant capital inflow into innovative drug ETFs, indicating a potential investment opportunity in the long term [1]. Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index fell by 4.7%, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 4.3% [1]. - The CSI Innovative Drug Industry Index declined by 1.5%, and the CSI Biotechnology Theme Index dropped by 1.2% [1]. - The CSI 300 Healthcare Index saw a smaller decline of 0.8% [1]. - Despite the overall market downturn, the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) recorded a net subscription of 34 million units throughout the day [1]. Group 2: Industry Growth and Valuation - The total value of License-out transactions for Chinese innovative drugs has increased from $2.562 billion in 2017 to $140.274 billion by 2025, reflecting enhanced international competitiveness [1]. - By 2025, over 70% of innovative drug companies are expected to achieve positive revenue growth, indicating that the industry is entering a commercialization phase [1]. - The current valuation of the pharmaceutical sector is considered attractive, with recommendations to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 3.1% [1] - The total value of China’s innovative drug License-out transactions grew from $2.562 billion in 2017 to $140.274 billion by 2025, indicating enhanced international competitiveness [1] - Over 70% of innovative drug companies are expected to achieve positive revenue growth by 2025, marking a transition into a commercialization phase for the industry [1] Group 2 - The current valuation of the pharmaceutical sector is considered attractive, with a recommendation to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1] - The ETF tracking the CSI Biotechnology Theme Index, managed by E Fund, has seen a decline of 0.3% [4] - The ETF tracking the CSI Pharmaceutical and Health Index, also managed by E Fund, has similarly decreased by 0.3% [4]

Core Insights - The article emphasizes the collective intelligence of investors, highlighting that the "Top Ten Core Asset Portfolio" launched by the company in 2019 has achieved a cumulative return of 274.61% by December 15, significantly outperforming the Shanghai and Shenzhen 300 Index and the Hang Seng Index [1] - In 2023, the company launched another portfolio called "Global Vision: Betting on China," which has recorded a 15.16% increase in 2024, outperforming the Wind All A Index by 5.16% [1] - As of December 26, 2025, the "Global Vision: Betting on China" portfolio has achieved a 29.72% increase, surpassing the Shanghai and Shenzhen 300 Index by 11.36 percentage points [1] ETF Performance Summary - The A500 ETF Fund (512050.SH) recorded a 25.58% increase in 2025 [2] - The ChiNext 50 ETF (159949.SZ) saw a remarkable increase of 60.67% [2] - The Hong Kong Innovation Drug ETF (513120) led the performance with a 71.86% increase [2] - The Semiconductor Theme ETF (588200.SH) experienced a decline of 59.15% [2] - The Internet Theme ETF (159792.SZ) increased by 24.033% [2] - The H-share ETF (510900.SH) rose by 21.58% [2] - The Consumption ETF (159928.SZ) decreased by 2.08% [2] - The Broker ETF (512000.SH) increased by 5.00% [2] - The S&P 500 ETF (513500.SH) recorded a 13.83% increase [2] Industry Highlights - The pharmaceutical sector has transformed from one of the worst-performing sectors to one of the strongest, with innovative drug companies frequently achieving record-breaking sales [3] - The total transaction volume for innovative drug license-out deals is expected to exceed $100 billion, accounting for nearly half of the global pharmaceutical business development transaction volume [4] - The Hong Kong Innovation Drug ETF (513120) tracks the China Hong Kong Innovation Drug Index, focusing on high-quality biotech companies in the Hong Kong market [4] - The ETF has a current scale of 24.1 billion yuan, with an average daily trading volume exceeding 5.3 billion yuan, making it the largest and most liquid thematic index fund in the market [4] - The ChiNext 50 ETF (159949) has also performed well, with a year-to-date increase of 59.86% and a significant increase of 129.61% since the "924" period [5][7] Market Trends - The ChiNext 50 Index employs a unique "liquidity-first, scale-second" strategy, selecting the 50 largest and most liquid stocks from the ChiNext 100, representing the core strengths of the ChiNext market [9] - The ETF's performance benefits from the dual advantages of leading stocks and sector rotation, particularly in the information technology and new energy sectors [9] - Looking ahead to 2026, the market is expected to benefit from continued overseas liquidity easing and domestic policies aimed at expanding domestic demand, which may improve the corporate profit environment [10]